NCT05006898View on ClinicalTrials.gov

Compound to Control Presbyopia Symptoms

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

July 1, 2020

Study Completion Date

July 1, 2020

Conditions
Presbyopia
Interventions
COMBINATION_PRODUCT

PBO to control presbyopia symptoms

Low dose PBO to control presbyopia symptoms

Trial Locations (1)

01090

Optall Vision, Mexico City

Sponsors

Lead Sponsor

Optall Vision
All Listed Sponsors
lead

Optall Vision

OTHER

NCT05006898 - Compound to Control Presbyopia Symptoms | Biotech Hunter | Biotech Hunter